Open AccessCoronavirus as a Catalyst for Digitalisation and Public-Private Partnership in Medicine
Author(s) -
Т. Н. Юдина,
А.М. Балашов
Publication year - 2021
Publication title -
mir novoj èkonomiki
Language(s) - English
Resource type - Journals
eISSN - 2220-7872
pISSN - 2220-6469
DOI - 10.26794/2220-6469-2021-15-1-100-111
Subject(s) - general partnership , swot analysis , work (physics) , pandemic , business , entrepreneurship , public relations , public–private partnership , civil society , covid-19 , quality (philosophy) , political science , russian federation , public administration , economic growth , economics , disease , economic policy , medicine , infectious disease (medical specialty) , finance , marketing , engineering , politics , mechanical engineering , philosophy , pathology , epistemology , law
The article focuses on the impact of the COVID-19 pandemic on digitalization and public-private partnerships (PPPs) in medicine. The epidemic of this disease has intensively affected Russia, and the viral economic crisis has highlighted the need for structural reforms in many sectors of the economy, including medicine. The Russian Federation’s budget regularly lacks funds to solve much pressing health care and science problems. In this regard, PPP is of particular interest, promoting better management and higher medical services quality. Therefore, the purpose of the work is to consider the forms of interaction of advanced medical institutions with entrepreneurship, scientific organizations, regional administrations, civil society and the possibility of increasing the potential of such cooperation. A methodological basis of our research was a synergistic approach to scientific knowledge, institutional, cluster, general scientific analysis of sources, which made it possible to establish key aspects of the interaction of agents, and the SWOT analysis method made it possible to show, with some examples, the impact of PPP not only on the development of medical institutions but also on efficiency activities of the company.